Success Metrics

Completion Rate

0%(0/3)

Active Trials

0(0%)

Terminated

3(100%)

Phase Distribution

Ph not_applicable

33%

Ph phase_1

67%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution3 total trials

Phase 1Safety & dosage

2(66.7%)

N/ANon-phased studies

1(33.3%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

0.0%

0 of 3 finished

Non-Completion Rate

100.0%

3 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Terminated(3)

Detailed Status

Terminated3

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

0.0%

Most Advanced

Phase 1

Trials by Phase

Phase 12 (66.7%)

N/A1 (33.3%)

Trials by Status

terminated3100%

Recent Activity

0 active trials

Showing 3 of 3

terminatedphase_1

Photodynamic Therapy Using Lutetium Texaphyrin in Treating Patients With Cervical Intraepithelial Neoplasia

NCT00005808

terminatednot_applicable

EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer

NCT00087191

terminatedphase_1

Photodynamic Therapy With Lutetium Texaphyrin in Treating Patients With Locally Recurrent Prostate Cancer

NCT00005067

Clinical Trials (3)

Showing 3 of 3 trials

NCT00005808Phase 1

Photodynamic Therapy Using Lutetium Texaphyrin in Treating Patients With Cervical Intraepithelial Neoplasia

Terminated

NCT00087191Not Applicable

EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer

Terminated

NCT00005067Phase 1

Photodynamic Therapy With Lutetium Texaphyrin in Treating Patients With Locally Recurrent Prostate Cancer

Terminated

All 3 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 3